Tissue Repair
KPV
KVP
Cut from the same parent hormone as PT-141, but works on a completely different pathway: no arousal effects, no pigmentation changes, just anti-inflammatory signalling. Most of the research sits in gut inflammation (colitis models in mice) and skin irritation, with some antimicrobial activity against bacteria including MRSA reported too. Like BPC-157 and TB-500, there's no completed human trial behind any of it. The strongest single dataset dates back to 2008, and it's animal data.
Preclinical anti-inflammatory tripeptide. Current evidence is cell and animal work rather than human therapeutic trials.
How well studied
Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied
Little to no real testing in humans at all. Mostly theory, lab results, or anecdote.
UK status
How you could legitimately come across it here, if at all
No authorised UK medicine contains this, and we have no record of a routine UK clinic route. Material sold online is unregulated.
Evidence strength and UK regulatory status answer different questions.
Heightened caution: this compound carries unresolved regulatory, safety or supply-chain concerns in the UK. Nothing here is a recommendation to use it.
Overview
How it works
Gets pulled into cells through a gut-lining transporter and jams a switch called NF-κB that turns on inflammation, without touching the arousal or pigmentation pathway its parent hormone uses.
Enters cells via the PepT1 transporter and inhibits NF-κB, blocking transcription of pro-inflammatory cytokines including TNF-α, IL-1β and IL-6, independent of activity.
Reported benefits
- Cell and mouse studies show anti-inflammatory effects, including reduced NF-kB-related signalling in colitis models
- No verified human clinical efficacy or safety dataset was found
Who it's typically used for
Timeline to results
Safety & UK access
Dosage
No established human dose. Zero completed dose-response trials, the same evidence gap as BPC-157 and TB-500.
Side effects
- Human safety profileinsufficient human data; no completed human trial identified
- Injection or oral route reactionsreported anecdotally only
Getting it in the UK
No authorised UK medicine contains this, and we have no record of a routine UK clinic route. Material sold online is unregulated.
Where it turns up
- Not routinely available in the UK
- Unregulated online market
No authorised UK medicinal product containing KPV was identified. Online availability does not establish quality, safety or authorisation.
Not MHRA-licensed; part of the same July 2026 US compounding review as BPC-157 and TB-500. No UK licensing pathway exists
MHRA: the UK regulator that assesses whether a medicine is safe and works before it can be authorised for use here. Something not being MHRA-licensed does not automatically mean it is illegal, and it does not mean it is safe.
This is background information about UK regulation, not advice about what you can or should obtain.
Evidence & sources
Why this rating?
The A to D rating shown above comes from our earlier editorial review and is still waiting to be migrated into the structured review record below. That is a gap in our record-keeping, not a sign the rating is wrong.
Evidence fingerprint
No route and indication scope has been published for this profile yet, so no fingerprint is shown.
Sources
Structured source audit not yet published for this profile. The references behind this page are being catalogued one compound at a time, and this one has not been through that process yet.
Content freshness
- Last reviewed
- 24 Sept 2026
- Regulatory status last checked
- 21 Aug 2026